Penn Medicine Abramson Cancer Center

 

Controversies and Update for Patient Care in Multiple Myeloma
17:23

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

UPenn Expert Analysis 40 y/o Patient With MM: How to Treat Systemically Today? How to Proceed After Initial Systemic Therapy? At What Point to Change Therapy?

FEATURING Edward Stadtmauer, Dan Vogl, Adam D. Cohen, Stephen Wallace
  • 33 views
  • March 3, 2021
10:17

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

UPenn Physicians Analyze a Challenging Case of MM: What Systemic Therapy to Start With? How to Proceed With 3 Months Post-Transplant Recurrence?

FEATURING Edward Stadtmauer, Dan Vogl, Adam D. Cohen, Stephen Wallace
  • 201 views
  • March 3, 2021
15:36

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

CAR-T and IO for R/R MM in 2021: Is bb2121 Safe and Does It Improve ORR? Does Cilta-Cel Improve PFS? How to Improve Clinical Outcomes?

FEATURING Adam D. Cohen
  • 29 views
  • March 2, 2021
15:36

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

bsAb and IO for R/R MM in 2021: Are Teclistamab, Talquetamab, & Cevostamab Showing Promising Activity?

FEATURING Adam D. Cohen
  • 31 views
  • March 2, 2021
22:31

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

2021 Experimental Therapies for Relapsed Myeloma: Antibodies (Dara, Isa, Elo), ADCs (Blenrep, MEDI2228), Small Molecules (Selinexor, Venetoclax), New Trials (Iberdomide, Melflufen, CPT, TAK-573, Tasquinimod)

FEATURING Dan Vogl
  • 80 views
  • March 2, 2021